05.04.2024 - Company presentation and fireside chat on April 11th at 11:45 a.m. ETCAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) - Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that .
08.01.2024 - - FHD-286 combination study in AML continues to progress in the clinic with data anticipated in the second half of 2024; preclinical combination data with FHD-286 and tyrosine kinase inhibitors (TKIs) in EGFR/KRAS resistance anticipated by the . Seite 1